There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC). To this end, the AUA created this course as part of its educational initiative to focus on resident and fellow training in the area of advanced prostate cancer and CRPC.
Maximum of 9.25 AMA PRA Category 1 Credits™
Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
Michael S. Cookson, MD, MMHC
David F. Jarrard, MD
This activity is designed for urology residents, fellows, advanced practice providers, urologists and other health care providers who care for patients with prostate cancer.
There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC). The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area. Additionally, the findings indicate that the AUA should continue to develop courses and educational materials specifically targeted at residents that covers the medical management of advanced prostate cancer.
The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer (CRPC). Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
The 2018 series is comprised of a variety of activities, including two live forums, four live webinars, webcasts and podcasts.
All activities are complimentary.
As the capstone to this initiative, a live, interactive forum will be held for participants to engage with subject matter expects and mentors. For convenience, participants can choose from one of two dates and locations.
At the conclusion of this activity, participants will be able to:
9 a.m. - 10 a.m.
10 a.m. – 10:10 a.m.
10:10 a.m. – 10:25 a.m.
10:25 a.m. – 10:45 a.m.
Initial Management and Imaging of Advanced Prostate Cancer
10:45 a.m. – 11:05 a.m.
Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer
11:05 a.m. – 11:25 a.m.
M0 CRPC: Emerging Treatment Options
11:25 a.m. – 11:45 a.m.
MDC and Review of CRPC Guidelines
11:45 a.m. – 12:15 p.m.
Case-Based Roundtable Discussions - Session I
12:15 p.m. - 12:20 p.m.
Session I Post-Test
12:20 p.m. - 1:35 p.m.
A Non-CME Lunch Symposium supported by Astellas Pharma US and Pfizer Oncology
1:35 p.m. – 1:55 p.m.
Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents
1:55 p.m. – 2:15 p.m.
Radionuclide Therapy and Bone Health
2:15 p.m. – 2:45 p.m.
Cased-based Roundtable Discussions - Session II
2:45 p.m. – 2:50 p.m.
Session II Post-Test
2:50 p.m – 3:10 p.m.
3:10 p.m. – 3:40 p.m.
Role of Chemotherapy and Performance Status and Pain Management
3:40 p.m. – 4:00 p.m.
Treatment Sequencing, Immunotherapy and Future Approaches
4:00 p.m. – 4:40 p.m.
Case-based Roundtable Discussion - Session III
4:40 p.m. – 4:45 p.m.
Session III Post-Test
4:45 p.m. – 5 p.m.
Sheraton Grand Phoenix
340 North 3rd Street
Phoenix, AZ 85004
Interact with the subject matter experts during four, live interactive webinars. For convenience, webinars will be limited to just one hour. Time and dates coming soon!
Can't make it to the live webinars? Content will be recorded and made available on AUAUniversity so that you can view a webcast or listen via podcast at a time and date that works best for you.
Michael S. Cookson, MD, MMHC
Professor and Chairman
University of Oklahoma - Department of Urology
Oklahoma City, OK
David F. Jarrard, MD
Professor and Vice Chairman of Clinical Affairs
University of Wisconsin School of Medicine and Public Health
All activities are complimentary.
AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before April 5, 2018. If AUA Education & Research cancels this course, notification will be sent by April 12, 2018.
Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email registration@AUAnet.org.
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).
Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions and audiotapes of such events and activities.
The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this live activity and enduring material for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
This educational series is supported by independent educational grants from:
To encourage and support the participant's care of their patients, this activity will provide resources to Urology Care Foundation existing resources on CRPC. These resources will include patient videos and brochures.
This is the Foundation's most comprehensive piece on advanced prostate cancer. It gives men and their loved ones struggling with their advanced diagnosis the tools to better manage their advanced prostate cancer symptoms.
This comprehensive piece on prostate cancer provides men and their loved ones struggling with their diagnosis the tools to better manage their prostate cancer symptoms.
This resource is a detailed guide on the diagnosis and treatment of advanced prostate cancer. Patients can use it to help them take control and be active participants in their care.
This fact sheet helps patients to better understand various advanced prostate cancers and how treatment can offer hope by extending a man's quality of life.
This fact sheet gives an overview of chemotherapy for prostate cnacer.
This fact sheet gives an overview of hormonal therapy for prostate cancer.
This fact sheet gives an overview of radiation therapy for prostate cancer.
An important fact sheet to review how to treat ED after prostate cancer treatment.
This fact sheet provides information about treating incontinence after prostate cancer treatment.
This nearly four-minute video is about metastatic castrate-resistant prostate cancer to help patients learn more about treatment options that will help them feel better and live longer.
In this five-minute video, survivors talk about their journey with prostate cancer.
A three-minute video helping patients to learn about what to expect after prostate cancer.
While viewing Guideline Statements on a desktop computer, use the left navigation to jump to different parts of the page.